FDA
-
-
-
-
-
-
-
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies
-
-
-
-
-
-
-
Oncolytics Biotech® Announces Update for Potential First-Line Pancreatic Cancer Registration Study
-
-
-
-
-
-
-
Oncolytics Biotech to delist from Toronto Stock Exchange on August 22
-
-
-
-
-
-
-
Oncolytics Biotech® to Engage FDA for Potential Registration-Enabled Study in First-Line Pancreatic Cancer with Goal to Launch Trial Activities by Year-End
-
-
-
-
-
-
-
Oncolytics Biotech® Appoints Former Ambrx Executive as Chief Business Officer to Drive Business Development Strategy
-
-
-
-
-
-
-
BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA’s Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 2025
-
-
-
-
-
-
-
Oncolytics Biotech® Funds Pelareorep's Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

